APVO earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -0.01. Updated 2026-07-23.
Aptevo Therapeutics (APVO) Research Hub
Aptevo Therapeutics (APVO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.5 USD (-6.83%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.01, market cap 0.01B. This hub links to the full technical, earnings and options research available for APVO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.5 USD (-6.83%) |
| 52-week range | 1.37 USD – 4.91 USD |
| Trend regime | Range |
| 14-day RSI | 21.7 (Oversold) |
| Trailing P/E | -0.01 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for APVO
Covered Call on APVO: how it works, illustrative setup around the real 1.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on APVO: how it works, illustrative setup around the real 1.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on APVO: how it works, illustrative setup around the real 1.5 USD price, max profit/loss, breakeven and when to use it. Educational.
APVO technical analysis: range, last 1.5 USD, RSI 21.7, 52w range 1.37 USD–4.91 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is APVO in?
Aptevo Therapeutics (APVO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is APVO in an uptrend or downtrend?
As of 2026-10-26, APVO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is APVO's trailing P/E ratio?
APVO's trailing P/E is -0.01, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does APVO next report earnings?
APVO is next scheduled to report earnings on 2026-08-10.